文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌治疗的地区差异:美国手术与放疗利用情况分析

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.
PubMed 文献 · Adv Radiat Oncol · 2019-01-23

该研究利用美国国家癌症数据库分析2010至2014年确诊的462811例局限性前列腺癌男性,按美国癌症协会分区划分为11个地区。结果显示63.46%接受根治性前列腺切除术、31.54%接受放疗、5.00%接受主动监测,地区间根治性前列腺切除术与放疗使用频率存在显著差异(P ≤ .0001)。

要点

  • 462811例局限性前列腺癌中,63.46%接受根治性前列腺切除术,31.54%接受放疗,5.00%接受主动监测。
  • 根治性前列腺切除术在中西部(75.07%)和高平原地区(73.37%)最常用,南大西洋地区最少(59.04%)。
  • 放疗在南大西洋地区(40.96%)和新英格兰地区(38.98%)最常用,中西部最少(24.93%)。

核心结论

  • 美国局限性前列腺癌的根治性治疗存在地区差异,这些地区差异的病因可能是多因素的。

研究设计与样本

  • 利用美国国家癌症数据库识别2010年至2014年确诊的局限性前列腺癌男性,按美国癌症协会分区将美国划分为11个地区。
  • 首次治疗记录为放疗(RT)、根治性前列腺切除术(RP)或主动监测(AS)。
  • 放疗亚组包括接受所有形式放疗(包括外照射和近距离放疗)或放疗联合雄激素剥夺治疗的患者;根治性前列腺切除术亚组包括接受单纯根治性前列腺切除术或联合放疗或雄激素剥夺治疗的患者。
  • 采用χ2检验评估地区与放疗和根治性前列腺切除术频率之间的关联。

主要发现

  • 研究纳入462811例在美国接受治疗的局限性前列腺癌男性,其中63.46%接受根治性前列腺切除术,31.54%接受放疗,5.00%接受主动监测。
  • 根治性前列腺切除术与放疗存在显著地区差异(P ≤ .0001)。
  • 根治性前列腺切除术在中西部(75.07%)和高平原地区(73.37%)最常用,在南大西洋地区(59.04%)最少用。
  • 放疗在南大西洋地区(40.96%)和新英格兰地区(38.98%)最常用,在中西部(24.93%)最少用。
  • 主动监测在新英格兰地区(7.27%)和中西部(6.8%)最常用,在高平原地区(2.57%)和中南部地区(2.84%)最少用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men with localized prostate cancer have various treatment options available in their management. The optimal approach is controversial and can be influenced by multiple factors. This study aimed to investigate the influence of geographic region on the selection of treatment for prostate cancer. METHODS AND MATERIALS: Using the National Cancer Database, we identified men diagnosed with localized prostate cancer between 2010 and 2014. The United States was divided into 11 regions per the American Cancer Society Divisions. The first course of treatment was recorded as radiation therapy (RT), radical prostatectomy (RP), or active surveillance (AS). The RT subgroup consisted of patients receiving all forms of RT, including external beam and brachytherapy, or RT plus androgen deprivation therapy. The RP subgroup consisted of patients receiving RP alone or combined with RT or androgen deprivation therapy. A χ2 test was performed to assess the association between region and frequency of RT and RP. RESULTS: This study included 462,811 men with localized prostate cancer who were treated in the United States, of whom 63.46% underwent RP, 31.54% underwent RT, and 5.00% underwent AS. Significant regional differences in RP and RT were observed (P ≤ .0001). RP was used most commonly in the Midwest (75.07%) and High Plains (73.37%) regions, whereas RP was least used in the South Atlantic (59.04%) region. Similarly, RT was used most commonly in South Atlantic (40.96%) and New England (38.98%) regions and least commonly in the Midwest (24.93%) region. AS was used most in the New England (7.27%) and Midwest (6.8%) regions and least used in the High Plains (2.57%) and Mid-South (2.84%) regions. CONCLUSIONS: Regional differences exist in the United States with regard to the definitive treatment of localized prostate cancer. The etiology for these regional differences is likely multifactorial.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Scherzer ND, DiBiase ZS, Srivastav SK, et al. Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States. Adv Radiat Oncol. 2019. PMID: 31011678. doi:10.1016/j.adro.2019.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。